<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033656</url>
  </required_header>
  <id_info>
    <org_study_id>NordicAOSD05</org_study_id>
    <secondary_id>2005-003173-24</secondary_id>
    <nct_id>NCT01033656</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study</brief_title>
  <acronym>NordicAOSD05</acronym>
  <official_title>An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jyväskylä Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, randomized, parallel-group, comparative, multicentre study. Patients on
      corticosteroids (plus conventional therapy) will be randomized to receive anakinra
      (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide, cyclosporin A
      or sulphasalazine. Patients enter the study if considered refractory to corticosteroids
      (prednisolone equivalent ≥10 mg/day) at the time of randomization.

      The randomized phase of the study will be followed by an open-label extension (OLE) phase, to
      follow-up drug survival, efficacy, tolerability and disease-related parameters of long-term
      treatment with anakinra or one of the study DMARDs or a combination of study drugs for
      additional 28 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Product: Kineret (anakinra) Comparative agents: Methotrexate or azathioprine or leflunomide
      or cyclosporin A or sulphasalazine Protocol title: An open, randomized study treating
      refractory adult-onset Still's disease with IL-1ra anakinra (Kineret, compared to an
      established, single anti-rheumatic treatment Target Disease: Adult-onset Still's disease
      Patients: 23 patients diagnosed with AOSD, living in the four Nordic countries.

      Study Objectives: To follow the changes in clinical status and disease activity in patients
      receiving anakinra, compared to those treated with an established DMARD, in addition to
      corticosteroids in patients with refractory AOSD. To compare the changes in disease-related
      parameters (global health, patient's assessment on disease, laboratory values) in the two
      randomized groups. To assess the safety of anakinra in AOSD. To follow-up drug survival,
      efficacy, tolerability and disease-related parameters of long-term treatment in AOSD (open
      phase).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reaching remission of the disease, after eight weeks of the randomized study treatment (Remission: afebrile and normalization of acute phase reactants)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Adult-Onset Still's Disease</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental drug of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparators:methotrexate, azathioprine, leflunomide or supfasalazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anakinra</intervention_name>
    <description>100 mg subcutaneous injection daily</description>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Interleukin-1 receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>comparators</intervention_name>
    <description>po drugs, comparators</description>
    <arm_group_label>comparator</arm_group_label>
    <other_name>methotrexate, azathioprine, leflunomide, sufalalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be diagnosed with AOSD according to preliminary classification by Yamaguchi
             (1992).

          -  Other diseases with similar symptoms must be excluded. Has been exposed to a
             corticosteroid for ≥2 months prior to randomization for AOSD.

          -  Needs a prednisolone dose ≥10 mg/day or equivalent, yet unacceptable disease activity
             determined by the investigator.

          -  Anti-TNF agents must be discontinued 4 to 8 weeks prior to commencing study
             medication.

        Exclusion Criteria:

          -  Use of corticosteroids (prednisolone equivalent &lt;10 mg/day.

          -  History of recurrent or chronic infection, including:

               -  tuberculosis

               -  any malignancy

               -  any other major chronic inflammatory disease syndrome

               -  drug or alcohol abuse

               -  known positivity for hepatitis B, C or HIV.

          -  Use of anti-TNF agents during ≤4 weeks (etanercept) or≤8 weeks (infliximab or
             adalimumab) prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan C Nordstrom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ann Kataja Knight</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Dan Nordstrom</investigator_full_name>
    <investigator_title>ass.prof</investigator_title>
  </responsible_party>
  <keyword>adult-onset Still's disease</keyword>
  <keyword>anakinra</keyword>
  <keyword>prednisolone</keyword>
  <keyword>disease-modifying antirheumatic drug</keyword>
  <keyword>methotrexate</keyword>
  <keyword>efficacy</keyword>
  <keyword>patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Still's Disease, Adult-Onset</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

